The Patent Finder
CI

Cybin Irl Limited

First filing 2021
OverviewNotableFeesChangesFamiliesPatent listSources & methods

11 patents currently held

1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in May 2041. from the record

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
May 2041
Next term end
5
Patent families

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
notable patents all others Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Feb 15, 2027
    The maintenance fee for Deuterated Tryptamine Derivatives and Methods of Use (US 11,724,985) comes due Feb 15, 2027. Unpaid by Aug 16, 2027, it lapses early.
  • 1 fee due Mar 5, 2027
    The maintenance fee for Deuterated Tryptamine Derivatives and Methods of Use (US 11,746,088) comes due Mar 5, 2027. Unpaid by Sep 7, 2027, it lapses early.
  • 1 fee due Jun 5, 2027
    The maintenance fee for Deuterated Tryptamine Derivatives and Methods of Use (US 11,834,410) comes due Jun 5, 2027. Unpaid by Dec 6, 2027, it lapses early.
  • 1 fee due Oct 16, 2027
    The maintenance fee for Deuterated Tryptamine Derivatives and Methods of Use (US 11,958,807) comes due Oct 16, 2027. Unpaid by Apr 17, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 2 of the patents on this record were granted since Aug 17, 2026

What they patent

Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.

Patents held now

Soonest term end first.
PatentTitleStatusExpiresConfidence
US 11,242,318Deuterated Tryptamine Derivatives and Methods of Use
In force
 · High confidence
In forceHigh confidence
US 11,724,985Deuterated Tryptamine Derivatives and Methods of Use
In force
 · High confidence
In forceHigh confidence
US 11,746,088Deuterated Tryptamine Derivatives and Methods of Use
In force
 · High confidence
In forceHigh confidence
US 11,834,410Deuterated Tryptamine Derivatives and Methods of Use
In force
 · High confidence
In forceHigh confidence
US 11,958,807Deuterated Tryptamine Derivatives and Methods of Use
In force
 · High confidence
In forceHigh confidence
US 12,110,272Deuterated Tryptamine Derivatives and Methods of Use
In force
 · Low confidence
In forceLow confidence
US 12,291,499Deuterated Tryptamine Derivatives and Methods of Use
In force
 · High confidence
In forceHigh confidence
US 12,751,940Methods for Delivery of Psychedelic Medications by Inhalation and Systems for Performing the Methods
In force
 · High confidence
In forceHigh confidence
US 12,122,741Therapeutic Phenethylamine Compositions and Methods of Use
In force
 · High confidence
In forceHigh confidence
US 12,735,386Psilocybin Analogs, Salts, Compositions, and Methods of Use
In force
 · High confidence
In forceHigh confidence
10 of 11 patents shown.
Pro members see all 11.
Pro members: see all 11 patents
Also on record, not counted in the 11: 1 patent in force now held by others · 23 applications pending · 1 application abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
1 terminal disclaimer is on file with no resolved reference. No cap is applied and none is guessed
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited